Oral opaganib delivers statistically significant increase in survival time in in vivo Ebola virus study
Oct. 4, 2023
Redhill Biopharma Ltd. has announced a survival benefit with its oral sphingosine kinase-2 (SPHK2) selective inhibitor opaganib (ABC-294640) in an in vivo Ebola virus study.
